This is a snippet of the transcript, sign up to read more.
On the other hand, there are big decisions, like deciding what type of activity the laboratory will continue to perform, building clusters of laboratories together when making acquisitions, for example, in France, sometimes with properties not owned by Eurofins. There were also decisions about grouping all laboratories into one unique campus built from scratch, sometimes owned by Eurofins or the Gilles Martin family. Those big decisions systematically came from Gilles Martin. We could make some decisions on our own, but the big decisions were clearly his, even if we disagreed. On the day-to-day, we had a lot of autonomy to deal with customers, pricing, and everything.
This is a snippet of the transcript, sign up to read more.
The testing business is complex and not easy to manage as a global contract. It's not like negotiating a price per kilo or per ton for raw materials. There are thousands of methods, and prices vary greatly depending on the matrix and other factors. This complexity makes it difficult for buyers to manage. In the water market, the margins are lower because it's standardized testing, so buyers can easily compare prices. But in food testing, it's more complex, leading to better margins but making it a nightmare for buyers.
This is a snippet of the transcript, sign up to read more.
I can tell you that in Nantes, it's around 100, a bit more than 100 euros per square meter a year, 120. It depends on the place and the building itself. The difficulty at Eurofins was that we were paying, as the operating company, way more than 200, 250 euros per square meter a year. The real estate company was paying and investing in some settings for the laboratory itself, such as HVAC for air replacement and cooling, which are very expensive.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research